Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
Date:11/9/2009

pipeline, including KRX-0401 and Zerenex; or the effect on our stock value of the other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    KERYX CONTACT:
    Lauren Fischer
    Director - Investor Relations
    Keryx Biopharmaceuticals, Inc.
    Tel: 212.531.5965
    E-mail: lfischer@keryx.com
                             Keryx Biopharmaceuticals, Inc.
                         Selected Consolidated Financial Data
                  (In Thousands, Except Share and Per Share Amounts)

                       Statements of Operations Information:

                                      Three Months Ended     Nine Months Ended
                                          September 30,        September 30,
                                          (unaudited)           (unaudited)
                                       2009        2008       2009       2008
                                       ----        ----       ----       ----
    REVENUE:
    License revenue                  $   --     $   327    $21,616     $  853
    Service revenue                      --          41          3        103
    Other revenue                     3,500          --      3,575         --
                                 --------------------------------------------
    TOTAL REVENUE                     3,500         368    
'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
3. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
4. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
5. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
6. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 The Physician-Patient Alliance for Health ... 28, 2015, "Surviving Your Hospital Stay: Physician-Patient Alliance ... Safety." A sentence was omitted from ... "PPAHS is a member of the National Coalition ... information on the National Coalition to Promote Continuous Monitoring ...
(Date:7/31/2015)... 2015  Xcelience, a contract development and manufacturing ... a structured cash investment in Powdersize, a ... micronization and powder size classification within the pharmaceutical ... while simultaneously adding a complete set of particle ... "As we continue to build ...
(Date:7/31/2015)... Ore., July 31, 2015  Semler Scientific, Inc. (Nasdaq: ... testing services to healthcare insurers and physician groups, today ... 30, 2015. "In the second quarter ... year revenue growth of 54%, quarter over quarter revenue ... the installed base of FloChec® units of 18%," said ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
(Date:7/31/2015)... , ... July 31, 2015 , ... ... the RenovoCath,™ a novel catheter that was developed for targeted delivery of fluids ... are now being treated at Florida Hospital Tampa with the device that provides ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Patients with higher ... to a study published today in Nature Communications and led by researchers from the ... suggests that variations in the gene RTN1 led to greater production of the related ...
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair transplant ... they are the latest recipients of the Center of Clinical Excellence for ARTAS ... worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration is ...
(Date:7/31/2015)... NB (PRWEB) , ... July 31, 2015 , ... Indosoft, ... script builder in Q-Suite 5.9. Q-Suite is their flagship contact center ACD system ... that the agent script display logic shows the script components to the agent only ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... release a newly redesigned website at Healthpointe.net. The new website will feature a ... , The redesign serves to provide smoother interactions between patients and the Healthpointe ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:Healthpointe Announces Newly Redesigned Website 2
... a technique to attack and destroy tumours without causing ... hair loss. ,They have used nanotechnology to ... leave healthy tissue unaffected. ,The particles - ... they zero in on their target. ,Traditional ...
... A chemical emergency struck Salisbury, suburb north of the Adelaide ... a five-year-old kid , sliding down in a popular ... ,It is not clear what happened to the ... out something had gone wrong. ,Health authorities described ...
... out of care do not live as long as those ... Medicine and Veterans Affairs researchers in a report published ... available on line. ,"In an era when highly ... causes AIDS) is keeping people alive, understanding the value of ...
... Britain have developed an artificial plastic blood, which they claim ... be a huge advantage in war zones. ... that have an iron atom at their core, like haemoglobin, ... researchers say they were looking for extra funding to develop ...
... for a Tasmanian school was convicted to a four-month jail ... and making pornography out of it. ,Adrian Alan ... indecency, one count of producing child exploitation material, and one ... used the school's own camera to take 36 pictures of ...
... To help people understand who is at risk for the disease, ... up some common myths about osteoporosis. ,1. MYTH: ... many more women who may develop this condition, theres also a ... In fact, roughly 2 million men suffer from osteoporosis, accounting for ...
Cached Medicine News:Health News:New Cancer Therapy That can Be Less Painful 2Health News:Children Using Slide in Playground Treated for Exposure to Poisoning 2Health News:HIV Survival Improves If Patients Stay in Care 2Health News:7 Common Myths About Osteoporosis 2Health News:7 Common Myths About Osteoporosis 3
Used for common bile duct exploration. Supplied sterile in peel-open packages. Intended for one-time use....
... with the MAMMOTOME® HH (Hand ... invasive procedure using ultrasound imaging ... images to locate breast abnormalities, ... and map the area you ...
... Provides reliable strength for temporary wound ... which compliant and stretchable support material ... transudate is not required. Predictable absorption. ... be inert, nonantigenic, and nonpyrogenic. ,VICRYL ...
... Mesh plugs perform best when the ... contact with a smooth wall of highly ... means less tissue remodeling to help stabilize ... fills more of the defect with gentle ...
Medicine Products: